Antidiabetic Drugs
SKU
MRR-437896AA366F
Region
Global
Publication Date
February 2024
Delivery
Immediate
2023
USD 46.93 billion
2030
USD 92.32 billion
2024
USD 51.42 billion
CAGR
10.14%
Antidiabetic Drugs Market by Type (Alpha-Glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors), Disease (Diabetes Mellitus Type 1, Diabetes Mellitus Type 2), Patient - Global Forecast 2024-2030

[199 Pages Report] The Antidiabetic Drugs Market size was estimated at USD 46.93 billion in 2023 and expected to reach USD 51.42 billion in 2024, at a CAGR 10.14% to reach USD 92.32 billion by 2030.

Antidiabetic Drugs Market
To learn more about this report, request a free sample copy
Antidiabetic Drugs Market - Global Forecast 2024-2030
To learn more about this report, request a free sample copy
FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antidiabetic Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antidiabetic Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antidiabetic Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Ltd., Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Cipla Limited, Dr. Reddy's Laboratories, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Mankind Pharma Ltd., Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Holdings Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Tonghua Dongbao Pharmaceutical Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Antidiabetic Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • Alpha-Glucosidase Inhibitors
    • Biguanides
    • DPP-IV (Dipeptidyl Peptidase) Inhibitors
    • GLP-1 (Glucagon-like Peptide) Agonists
    • Insulin
      • Intermediate-Acting Insulin
      • Long-Acting Analog
      • Premixed Insulin
      • Rapid-Acting Analog
      • Short-Acting Analog
    • Meglitinides
    • SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
    • Sulphonylureas
    • Thiazolidinedione
  • Disease
    • Diabetes Mellitus Type 1
    • Diabetes Mellitus Type 2
  • Patient
    • Adult
    • Geriatric
    • Pediatric

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Antidiabetic Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antidiabetic Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Antidiabetic Drugs Market?
  4. What is the market share of the leading vendors in the Antidiabetic Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Antidiabetic Drugs Market?

Table of Contents
  1. Preface
  2. Research Methodology
  3. Executive Summary
  4. Market Overview
  5. Market Insights
  6. Antidiabetic Drugs Market, by Type
  7. Antidiabetic Drugs Market, by Disease
  8. Antidiabetic Drugs Market, by Patient
  9. Americas Antidiabetic Drugs Market
  10. Asia-Pacific Antidiabetic Drugs Market
  11. Europe, Middle East & Africa Antidiabetic Drugs Market
  12. Competitive Landscape
  13. Competitive Portfolio
Companies Mentioned
  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Holdings Corporation
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Antidiabetic Drugs Market
The Global Antidiabetic Drugs Market size was estimated at USD 46.93 billion in 2023 and expected to reach USD 51.42 billion in 2024.
The Global Antidiabetic Drugs Market to grow USD 92.32 billion by 2030, at a CAGR of 10.14%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.